Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Receivables - Net (2021 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Receivables - Net for 3 consecutive years, with $79604.0 as the latest value for Q2 2023.

  • Quarterly Receivables - Net rose 1114.96% to $79604.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $79604.0 through Jun 2023, up 1114.96% year-over-year, with the annual reading at $39881.0 for FY2022, 63.79% down from the prior year.
  • Receivables - Net for Q2 2023 was $79604.0 at Inhibikase Therapeutics, up from $64521.0 in the prior quarter.
  • The five-year high for Receivables - Net was $110141.0 in Q4 2021, with the low at $6552.0 in Q2 2022.
  • Average Receivables - Net over 3 years is $51788.1, with a median of $47976.0 recorded in 2022.
  • The sharpest move saw Receivables - Net tumbled 63.79% in 2022, then skyrocketed 1114.96% in 2023.
  • Over 3 years, Receivables - Net stood at $110141.0 in 2021, then crashed by 63.79% to $39881.0 in 2022, then soared by 99.6% to $79604.0 in 2023.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $79604.0, $64521.0, and $39881.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.